NCT01119118 2019-11-21ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate CancerUniversity of Wisconsin, MadisonPhase 2 Terminated6 enrolled 6 charts
NCT00055471 2012-10-31A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate CancerAstraZenecaPhase 2 Completed22 enrolled 17 charts